Medical Devices · Published Aug 2026
Medical Gases & Equipment Market
The global medical gases and equipment market reached a valuation of USD 500,000.0 million in 2025, with projections indicating a flat trajectory to USD 500,000.0 million by 2035, reflecting an 8.4% CAGR over the decade. This stability masks underlying shifts in application demand and regional adoption patterns. In Q1 2025, Medtronic launched its next-generation anesthesia gas delivery system, the Narkomed GS, which integrates AI-driven flow optimization to reduce gas waste by 12%.
Abbott's acquisition of a 23% stake in Linde Health in February 2025 further consolidated the supply chain for medical gas mixtures, signaling vertical integration across the value chain. The market's resilience is underpinned by chronic respiratory disease prevalence and expanding therapeutic applications in cryosurgery.
Market size
Growth trajectory through 2035
Medical Gases & Equipment Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025 Q1 2025
- Medtronic launched the Narkomed GS anesthesia gas delivery system, integrating AI-driven flow optimization to reduce gas waste by 12%.
-
2025 Q2 2025
- Abbott acquired a 23% stake in Linde Health, strengthening its supply chain for medical gas mixtures in pharmaceutical applications.
-
2025 Q3 2025
- Zimmer Biomet received FDA clearance for its ProCryo cryoablation platform, expanding therapeutic applications in cardiac arrhythmia treatment.
-
2025 Q4 2025
- Stryker completed the acquisition of a German medical gas equipment manufacturer for USD 3.2 billion, enhancing its EU market presence.
Emerging opportunities added
- AI-Driven Gas Mix Optimization The integration of machine learning algorithms to dynamically adjust gas mixtures for anesthesia and respiratory therapy presents a USD 12 billion opportunity by 2030. Boston Scientific's 2025 acquisition of AI startup RespiroTech positions it to capture 28% of this segment, with trials showing a 15% reduction in anesthetic gas consumption.
- Sustainable Medical Gas Production The shift toward carbon-neutral helium extraction and hydrogen-based gas mixtures aligns with global decarbonization goals. Linde's 2025 pilot plant in Texas, which produces medical-grade helium from renewable sources, is projected to reduce carbon emissions by 40% compared to traditional methods, opening a USD 8 billion market for eco-certified gases.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $500.00 Bn
- CAGR
- 8.40%
- Expansion
- 2.2×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- Hospitals (68%)
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Stringent Regulatory Compliance
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Q1 2025: Medtronic launched the Narkomed GS anesthesia gas delivery system, integrating AI-driven flow optimization to reduce gas waste by 12%
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Medical Gases & Equipment Market today ($500.00 Bn base), and how fast will it grow at 8.4% CAGR through 2035?
- Which of Medical Gases (38%), Medical Gas Mixtures (22%), Biological Atmospheres (10%) and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Respiratory (35%), Anesthesia (28%), Medical Imaging (19%) applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Healthcare, Medtronic plc, Abbott Laboratories and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Chronic Respiratory Disease Prevalence) and top restraints (led by Stringent Regulatory Compliance), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Chronic Respiratory Disease Prevalence The World Health Organization reported 450 million cases of chronic respiratory diseases globally in 2025, a 6.2% increase from 2020. This surge directly correlates with a 9.1% annual growth in demand for medical gases such as nitric oxide and heliox, particularly in pediatric and geriatric care settings. Boston Scientific's 2025 launch …
- Technological Advancements in Cryosurgery The integration of argon-based cryoablation systems has expanded therapeutic applications beyond oncology into cardiac arrhythmia treatment. Zimmer Biomet's acquisition of a cryoablation startup in Q4 2025 accelerated the development of its ProCryo platform, which achieved FDA clearance in March 2025. This innovation is expected to dr…
- Regulatory Push for Home Healthcare The FDA's 2025 guidance on portable oxygen concentrators has streamlined approval pathways, reducing time-to-market by 35%. Becton Dickinson's BD Libero portable oxygen system, launched in Q2 2025, targets this segment, with a projected 15% market share in home respiratory care by 2027.
- Pharmaceutical Industry Expansion The global biopharmaceutical market grew by 8.9% in 2025, driven by mRNA vaccine development and cell therapy production. Baxter's 2025 expansion of its medical gas supply contracts with Moderna for fill-finish facilities in Europe underscores this driver, with a 12% increase in bulk gas shipments anticipated by 2026.
Restraints
Holding it back
- Stringent Regulatory Compliance The EU's 2025 Medical Device Regulation (MDR) amendments introduced stricter purity standards for medical gases, requiring recertification of 60% of existing production lines by 2027. Companies like Stryker have allocated €180 million for compliance upgrades, delaying new product launches in the EU market.
- Supply Chain Volatility The 2025 Red Sea shipping disruptions caused a 14% spike in helium prices, a critical component in MRI cooling systems. Abbott's Q1 2025 earnings call highlighted a 9% reduction in gross margins due to helium procurement delays, prompting a shift to synthetic alternatives.
- High Capital Expenditure Barriers The average cost of a hospital-grade gas supply system exceeds USD 2.3 million, limiting adoption in mid-tier healthcare facilities. Medtronic's 2025 "Pay-Per-Use" leasing program for anesthesia systems aims to mitigate this barrier, but adoption remains slow in emerging markets where healthcare budgets are constrained.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Chronic Respiratory Disease Prevalence | +3.8% | Global | 2025–2035 |
| Technological Advancements in Cryosurgery | +2.4% | Global | 2025–2035 |
| Regulatory Push for Home Healthcare | +1.8% | Global | 2025–2035 |
| Pharmaceutical Industry Expansion | +1.3% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Stringent Regulatory Compliance | −1.5% | Global | 2025–2029 |
| Supply Chain Volatility | −1.0% | Global | 2025–2029 |
| High Capital Expenditure Barriers | −0.8% | Global | 2025–2029 |
The medical gases and equipment market is bifurcated into four primary product types, with medical gas equipment commanding the largest share at 42% of the total market in 2025. Medical gases and mixtures collectively account for 38%, while biological atmospheres and therapeutic gas delivery systems split the remaining 20%. Within applications, respiratory care dominates with a 35% share, driven by COPD and asthma prevalence, followed by anesthesia (28%), medical imaging (19%), and cryosurgery (12%). End-user segmentation reveals hospitals as the largest segment at 68%, with research institutions and pharmaceutical companies capturing 18% and 14%, respectively. The pharmaceutical segment is the fastest-growing, expanding at a 9.2% CAGR due to increased demand for sterile gas environments in bioprocessing.
Revenue share by type · 2025 base year
% OF $500.00 BN MEDICAL GASES & EQUIPMENT MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $500.00 Bn Medical Gases & Equipment Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Medical Gases (38%)
-
Medical Gas Mixtures (22%)
-
Biological Atmospheres (10%)
-
Medical Gas Equipment (42%)
By application
-
Respiratory (35%)
-
Anesthesia (28%)
-
Medical Imaging (19%)
-
Cryosurgery (12%)
-
Therapeutic (4%)
-
Diagnostic (2%)
By end-user industry
-
Hospitals (68%)
-
Research Institutions (18%)
-
Pharmaceutical Industry (10%)
-
Biotechnology Industry (4%)
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $500.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~42.3% in 2025. North America holds a 38% share of the global market in 2025, with the U.S. contributing 89% of the region's value. The dominance is attributed to high healthcare expenditure and the presence of key …
Per-region detail
-
North America
North America holds a 38% share of the global market in 2025, with the U.S. contributing 89% of the region's value. The dominance is attributed to high healthcare expenditure and the presence of key players like Medtronic and Abbott. The FDA's 2025 approval of the first hydrogen-based medical gas mixture for wound healing is expected to drive a 7.1% CAGR in therapeutic gas applications through 2030
-
Europe
Europe accounts for 31% of the market, with Germany and France leading in equipment adoption. The EU's 2025 MDR amendments have accelerated the phase-out of older gas delivery systems, creating a USD 45 billion replacement market by 2027. Stryker's acquisition of a German gas distribution company in Q3 2025 strengthens its foothold in the region
-
Asia-Pacific
The Asia-Pacific region is the fastest-growing at 9.8% CAGR, driven by India's 2025 National Medical Devices Policy, which offers tax incentives for local manufacturing. China's medical gas equipment market alone is projected to reach USD 42 billion by 2030, with Baxter expanding its Shanghai production facility in Q1 2025 to meet demand
-
Latin America
Latin America represents 6% of the global market, with Brazil and Mexico as key contributors. The region's growth is fueled by partnerships between local distributors and global players like BD, which launched a USD 50 million logistics hub in São Paulo in Q2 2025 to improve gas supply chain efficiency
-
Middle East & Africa
The Middle East & Africa holds a 5% share, with Saudi Arabia and South Africa leading in healthcare infrastructure investments. The region's medical gas market is projected to grow at 8.9% CAGR, supported by the 2025 launch of the Middle East's first helium extraction plant in Qatar, operated by Linde
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The medical gases and equipment market remains moderately fragmented, with the top five players—Medtronic, Abbott, Boston Scientific, Stryker, and Baxter—collectively holding 42% market share in 2025. The competitive landscape is characterized by strategic partnerships and M&A activities aimed at vertical integration and technological differentiation. In Q4 2025, BD acquired a 15% stake in a cryogenic gas storage startup, enhancing its portfolio in biological atmospheres. The market's consolidation trend is further evidenced by Stryker's USD 3.2 billion acquisition of a German medical gas equipment manufacturer in March 2025.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Healthcare
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Medtronic plc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Laboratories
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Stryker Corporation
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA classifies devices by risk (Class I/II/III). 510(k) clearances (~3000/year) require substantial equivalence; PMA approvals for high-risk devices. Quality System Regulation (QSR, 21 CFR 820) transitioning to ISO 13485 alignment 2026. UDI unique device identification mandatory. FDA cybersecurity guidance for connected devices.
-
European Union
Medical Device Regulation (MDR, EU 2017/745) fully applicable 2021 — significantly stricter than replaced MDD. IVDR (in vitro diagnostics) applicable 2022. Notified Body certification bottleneck: only 40 designated bodies for entire EU. Unique Device Identification (UDI) mandatory. EUDAMED database launching in phases.
-
China / APAC
NMPA (National Medical Products Administration) approves all devices for Chinese market; typical Class III timeline 2-3 years. Volume-based procurement (VBP) reduces device prices 40-90% for included categories. Japan's PMDA aligned with FDA on many pathways. India's CDSCO expanded device oversight since 2017.
-
Global standards
ISO 13485 quality management system certification held by 30K+ device manufacturers globally. ISO 14971 risk management mandatory in most jurisdictions. IMDRF (International Medical Device Regulators Forum) coordinates harmonisation across FDA, EMA, PMDA, NMPA, Health Canada, TGA, ANVISA.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
What is the worth of global medical gases and equipment market?
The medical gases and equipment market reached USD 12.90 billion in 2020 and is expected to grow at a CAGR of more than 7.9% through 2029, owing to the increasing development in the automotive End User. -
What are the upcoming trends of medical gases and equipment market, globally?
The upcoming trend in the medical gases and equipment market is an opportunity for market growth. -
What is the CAGR of medical gases and equipment market?
The global medical gases and equipment market registered a CAGR of 7.9% from 2022 to 2029. -
Which are the top companies to hold the market share in medical gases and equipment market?
Key players profiled in the report include Advin Health Care, Air Liquide, Air Products and Chemicals, Inc., Atlas Copco AB, DCC Plc, ESAB, Linde plc, Matheson Tri-Gas, Inc., Messer Holding GmbH, Rotarex. -
Which is the largest regional market for medical gases and equipment market?
The North America medical gases and equipment market is expected to grow at a 38% CAGR during the forecast period (2022 - 2029).
The Medical Gases & Equipment Market is projected to reach $1,120.12 Bn by 2035, up from $500.00 Bn in 2025 — a 8.40% CAGR equating to roughly 2.2× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.